Artivion (AORT) to Release Quarterly Earnings on Thursday

Key Points

• Q1 2026 earnings due May 7 after the close; analysts expect $0.06 EPS and about $115.78 million in revenue.
• In the prior quarter Artivion beat estimates with $0.17 EPS and $118.3 million in revenue (up 19.2% YoY); shares recently opened at $34.61 (down 4.7%), with a market cap of $1.68 billion and a P/E of 173.06.
• Analyst sentiment is a consensus "Moderate Buy" with a $51.00 price target (seven Buy, one Hold), while insiders sold 133,043 shares (~$4.98M) over the last quarter and now own 6.30% of the stock.

Artivion (NYSE:AORT - Get Free Report) is expected to be announcing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $115.7760 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion's quarterly revenue was up 19.2% compared to the same quarter last year. On average, analysts expect Artivion to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Stock Down 4.7%

Shares of Artivion stock opened at $34.61 on Thursday. Artivion has a twelve month low of $23.04 and a twelve month high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The company's 50 day moving average is $36.64 and its 200 day moving average is $41.36. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 173.06 and a beta of 1.63.

Analyst Ratings Changes

AORT has been the topic of several research analyst reports. Weiss Ratings raised Artivion from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, February 20th. LADENBURG THALM/SH SH raised Artivion from a "neutral" rating to a "buy" rating and set a $42.00 price objective for the company in a report on Friday, April 10th. Canaccord Genuity Group reduced their price objective on Artivion from $51.00 to $48.00 and set a "buy" rating for the company in a research report on Friday, February 13th. Needham & Company LLC reissued a "buy" rating on shares of Artivion in a report on Monday, April 20th. Finally, Stifel Nicolaus set a $55.00 target price on Artivion in a research report on Thursday, March 5th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Artivion currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

Insider Buying and Selling at Artivion

In related news, EVP Lance A. Berry sold 6,316 shares of the firm's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $238,618.48. Following the transaction, the executive vice president directly owned 210,827 shares of the company's stock, valued at approximately $7,965,044.06. This trade represents a 2.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John E. Davis sold 4,573 shares of Artivion stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $172,767.94. Following the transaction, the insider owned 230,794 shares in the company, valued at $8,719,397.32. This trade represents a 1.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 133,043 shares of company stock worth $4,977,158. 6.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AORT. Entropy Technologies LP grew its stake in shares of Artivion by 6.0% during the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company's stock valued at $251,000 after acquiring an additional 310 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Artivion during the 4th quarter worth approximately $248,000. State of Wyoming lifted its holdings in Artivion by 161.0% during the fourth quarter. State of Wyoming now owns 4,940 shares of the company's stock valued at $225,000 after purchasing an additional 3,047 shares in the last quarter. Lido Advisors LLC purchased a new position in Artivion during the third quarter valued at approximately $222,000. Finally, Hancock Whitney Corp bought a new position in shares of Artivion in the third quarter worth approximately $212,000. Institutional investors own 86.37% of the company's stock.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.